Coagulopathy, following medical therapy, for carcinoma of the prostate

Hematology

Volumn 10, Issue 1, 2005, Pages 65-68

  Bern, Murray M ^a  

^a Cancer Center of Boston   (United States)

Author keywords

Coagulopathy; Diffuse intravascular coagulation; Hormone therapy; Prostate cancer

Indexed keywords

AMINOCAPROIC ACID; ANTIANDROGEN; FLUTAMIDE; GONADORELIN; HEPARIN; LEUPRORELIN; PROCOAGULANT; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; AGED; ARTICLE; BLOOD CLOTTING DISORDER; CANCER HORMONE THERAPY; CASE REPORT; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; HEMATOMA; HUMAN; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; BLOOD COAGULATION DISORDERS; DISSEMINATED INTRAVASCULAR COAGULATION; DRUG THERAPY, COMBINATION; FIBRINOLYSIS; FLUTAMIDE; HUMANS; LEUPROLIDE; MALE; PROSTATIC NEOPLASMS;

EID: 23244443945     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330410001701594     Document Type: Article

References (50)

1. Rappaport SI, Chapman CG. Coexistent hypercoagulability and hypofibrinogenemia in a patient with prostatic carcinoma. Am. J. Med. 1959;27:144-153.
2. Burgess NA, Hudd C, Rees RW. Haemostatic pitfalls in advanced prostatic cancer. Br. J. Urol. 1993;71:231-233.
3. Tagnon HJ, Whitemore Jr., WF, Shulman NR. Fibrinolysis in metastatic cancer of the prostate. Cancer 1952;5:9-12.
4. Gans H. Is primary fibrinolysis a real entity? Surg. Gynecol. Obstet. 1973;136:975-976.
5. Frick PG. Acute hemorrhagic syndrome with hypofibrinogenemia in metastatic cancer. Acta Haematol. (Basel) 1956;16:11-29.
6. Mertens BF, Greene LF, Bowie EJW, et al. Fibrinolytic split products (FSP) and ethanol gelation test in preoperative evaluation of patients with prostatic disease. Mayo Clin. Proc. 1974;49:642-646.
7. Sack GH, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathologic and therapeutic features. Medicine 1977;56:1-37.
8. Betkurer V, Guinan P, Verma A, Morillo E, Ablin RJ, Sparkuhl A, Cochin A. Effect of transurethral resection on coagulation in carcinoma of prostate. Urology 1979;13:142-144.
9. Adamson AS, Francis JL, Witherow RO, Snell ME. Coagulopathy in the prostate cancer patient: prevalence and clinical relevance. Ann. R. Coll. Surg. Engl. 1993;75:100-104.
10. Samaha RJ, Bruns NC, Ross Jr., GJ. Chronic intravascular coagulation in metastatic prostate cancer. Arch. Surg. 1973;106:295-298.
11. Drewinko B, Cobb P, Guinee V, Giacco G, Trujillo JM, von Eschenbach A. Untreated prostate carcinoma is not associated with thrombohemorrhagic disorders. Urology 1987;30:11-17.
12. Kohli M, Fink LM, Spencer HJ, Zent CS. Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul. Fibrinolysis 2002;13:1-5.
13. Francis L. Haemostasis and cancer. Med. Lab. Sci. 1989;46:331-346.
14. Phillips LL, Shrodelis V, Furey CA. The fibrinolytic system in prostatic cancer. Cancer 1959;12:721-730.
15. Harvey MH, Osborn DE, Hutchinson RM. Disseminated intravascular coagulation following transrectal prostatic biopsy. Br. J. Urol. 1987;59:363-364.
16. Friedman NJ, Hoag MS, Robinson AJ, Aggeler PM. Hemorrhagic syndrome following transurethral prostatic resection for benign adenoma. Arch. Intern. Med. 1969;124:341-349.
17. Rader ES. Hematologic screening tests in patients with operative prostatic disease. Urology 1978;11:243-246.
18. Leong C, McKenzie MR, Coupland DB, Gascoyne RD. Disseminated intravascular coagulation in a patient with metastatic prostate cancer: fatal outcome following Strontium-89 therapy. J. Nucl. Med. 1994;35:1662-1664.
19. Lock M, Loblaw DA, Choo R, Imrie K. Disseminated intravascular coagulation and PC-SPES; a case report and literature review. Can. J. Urol. 2001;8:1326-1329.
20. Byar DP. The veterans administration cooperative urological research group's studies of cancer of the prostate. Cancer 1973;32:1126.
21. Cornfield DB, Rossman RE. Diethylstilbestrol-diphosphate-induced disseminated intravascular coagulation in prostatic carcinoma. South. Med. J. 1982;75:248-249.
22. Al-Mondhiry H, Manni A, Owen J, Gordon R. Hemostatic effects of hormonal stimulation in patients with metastatic prostate cancer. Am. J. Hematol. 1988;28:141-145.
23. Coune A, Brassinne C, Nijs M. Proteolytic and fibrinolytic factors in the human prostate. Thromb. Haemostatis 1974;41:628-630.
24. Brassinne C, Coune A, Nijs M, Tagnon H. Characterization of two direct fibrinolytic activities and of one proteolytic inhibitor activity in human prostate. Thromb. Res. 1976;8:803-818.
25. Coleman RW, Rubin RN. Disseminated intravascular coagulation due to malignancy. Semin. Oncol. 1990;17:172-186.
26. Debs R, Slichhter SJ. High dose estrogen therapy rapidly resolves disseminated intravascular coagulation. Proc. An. Meet Am. Soc. Clin. Oncol. 1985;4:265, (abs).
27. Goldenberg SL, Fenster NH, Perler Z, McLoughlin MG. Disseminated intravascular coagulation in carcinoma of prostate: Role of estrogen therapy. Urology 1983;22:130-132.
28. Lowe FC, Somers WJ. The use of ketoconazole in the emergency management of disseminated intravascular coagulation due to metastatic prostatic cancer. J. Urol. 1987;137:1000-2002.
29. Litt MR, Bell WR, Lepor HA. Disseminated intravascular coagulation in prostatie carcinoma reversed by ketoconizole. JAMA 1987;258:1361-1362.
30. Trachtengerg J, Halpern N, Pont A. Ketoconazole; a novel and rapid treatment for advanced prostate cancer. J. Urol. 1983;130:152-153.
31. Bhadoria DP, Mukhopadhyay DK, Mehta S, Mittal D, Rao YV, Malhotra KK. Emergency treatment with ketoconazole in disseminated intravascular coagulation due to metastatic prostatic. Assoc. Physicians India 1989;37:792-793.
32. Fleyel M, Leroy B, Plouvier F, Balin C, Marecaux O, Scherpereel P, Ann. Fr. Anesth. Reanim. 1991;10:406-408.
33. Chakrapee-Sirisuk S, Amornpichetkul K, Visudhiphan S, Sangruchi T, Srimuninnimit V, Sinlarat P. Ketoconazole and flutamide in the treatment of disseminated intravascular clotting from prostate cancer: a case report and review. J. Med. Assoc. Thai. 2001;84:1495-1501.
34. Smith MR. Successful treatment with mitozantrone chemotherapy of acute disseminated instravascular coagulation due to metastatic androgen independent prostate cancer. J. Urol. 2000;163:248.
35. Avances C, Jacot W, Senesse P, Culine S. Prompt resolution of acute disseminated intravascular coagulation with docetaxel and cisplatin in hormone refractory prostate cancer. J. Urol. 2002;168:1496.
36. Ruffion A, Manel A, Valignat C, Lopez JG, Perrin-Fayolle O, Perrin P. Succesful use of samarium 153 for emergency treatment of disseminated intravascular coagulation due to metastatic hormone refractory prostate cancer. J. Urol. 2000;164:782.
37. Nilsson IM, Anderson L, Bjorkman SE. Epsilon-aminocaproic acid (E-ACA) as a therapeutic agent: based on 5 years clinical experience. Acta Med. Scand. 1966;448(suppl):1-46.
38. Cooper DL, Sandler AB, Wilson LD, Duffy TP. Disseminated intravascular coagulation and excessive flbrinolysis in a patient with metastatic prostate cancer. Response to epsilon-aminocaproic acid. Cancer 1992;70:656-658.
39. Ratnoff OD. Epsilon aminocaproic acid: a dangerous weapon. N. Engl. J. Med. 1969;280:1124-1125.
40. Varenhorst E, Risberg B. Effects of estrogen, orchidectomy, and cyproterone acetate on tissue flbrinolysis in patients with carcinoma of the prostate. Investig. Urol. 1981;18:355-357.
41. Henriksson P, Blomback M, Bratt G, Edhag O, Eriksson A. Activators and inhibitors of coagulation and fibrinolysis in patients with prostatic cancer treated with estrogen or orchidectomy. Thromb. Res. 1986;44:783-791.
42. Blomback M, Hedlund PO, Sawe U. Changes in blood coagulation and fibrinolysis in patients on different treatment regimens for prostatic cancer. Predictors for cardiovascular complications? Thromb. Res. 1988;49:111-121.
43. Zistek Z, Iwan-Zietek I, Kotschy M, Tyloch F. Levels of plasminogen and alpha 2-antiplasmin in blood of patients with prostatic tumor. Pol. Tyg. Lek. 1996;51:86-88.
44. Geenen RW, Delaere KP, van Wersch JW. Coagulation and flbrinolysis activation markers in prostatic carcinoma patients. Eur. J. Clin. Chem. Clin. Biochem. 1997;35:69-72.
45. Iwan-Zietek I, Zietek Z, Kotschy M, Rosc D, Tyloch F. Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma. Pol. Tyg. Lek. 1996;51:91-93.
46. Pfluger H, Kirchheimer J, Ritschl P, Koller A, Hienert G, Binder BR. Tissue plasminogen activator activity in early prostatic cancer in bone metastases of prostatic cancer. Wien. Klim. Wochenschr. 1984;96:658-661.
47. Koller A, Kirchheimer J, Pfluger H, Binder BR. Tissue plasminogen activator activity in prostatic cancer. Eur. Urol. 1984;10:389-394.
48. Plas E, Carroll VA, Jilch R, Mihaly J, Vesely M, Ulrich W, Pfluger H, Binder BR. Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer. Int. J. Cancer 1998;78:320-325.
49. Lyon PB, See WA, Xu Y, Cohen MB. Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines. Prostate 1995;27:179-186.
50. Nakashima J, Tachibana M, Ueno M, Baba S, Tazaki H. Tumor necrosis factor and coagulopathy in patients with prostate cancer. Cancer Res. 1995;55:4881-4885.